|
|
Vericel Corporation (VCEL) |
|
Price: $41.6900
$1.60 
3.991%
|
| Day's High:
| $41.84
| Week Perf:
| 1.53 %
|
| Day's Low: |
$ 39.80 |
30 Day Perf: |
-5.83 % |
| Volume (M): |
335 |
52 Wk High: |
$ 54.10 |
| Volume (M$): |
$ 13,974 |
52 Wk Avg: |
$43.62 |
| Open: |
$40.00 |
52 Wk Low: |
$31.82 |
|
|
| Market Capitalization (Millions $) |
2,030 |
| Shares
Outstanding (Millions) |
49 |
| Employees |
280 |
| Revenues (TTM) (Millions $) |
215 |
| Net Income (TTM) (Millions $) |
1 |
| Cash Flow (TTM) (Millions $) |
5 |
| Capital Exp. (TTM) (Millions $) |
45 |
Vericel Corporation
Vericel Corporation is a publicly traded biopharmaceutical company that focuses on developing and commercializing cell therapy products that repair or regenerate human tissue.
The company is headquartered in Cambridge, Massachusetts, and has facilities in Michigan and California.
Vericel's flagship product is called MACI, which stands for Matrix-Induced Autologous Chondrocyte Implantation.
This is a regenerative medicine treatment for patients with knee cartilage damage or disorders.
MACI involves harvesting a patient's own healthy cartilage cells, multiplying them in a laboratory, and then implanting them into the affected area of the knee.
MACI received FDA approval in 2016 and has since been used in thousands of patients.
In addition to MACI, Vericel also sells Epicel, which is a cell-based therapy for treating severe burns.
Epicel involves taking a small sample of a patient's own healthy skin cells, multiplying them in a laboratory, and then grafting them onto the burn wound.
Epicel has been used in over 1,000 patients and is the only FDA-approved cell therapy for the treatment of severe burns.
Vericel has a robust research and development pipeline focused on cell therapy products that target cardiac, pulmonary, and neurological diseases.
The company is committed to advancing science and technology to bring innovative treatments to patients suffering from debilitating conditions.
Overall, Vericel Corporation is a leading player in the field of regenerative medicine, with a focus on developing cell-based therapies that improve patients' quality of life.
Company Address: 64 Sidney Street Cambridge 2139 MA
Company Phone Number: 588-5555 Stock Exchange / Ticker: NASDAQ VCEL
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Thu, Aug 15 2024 8:05 PM UTC
'Vericel Announces FDA Approval of NexoBrid for Pediatric Severe Thermal Burns, Expanding Target Customer Base to Include Pediatric Burn Centers'In a landmark achievement, Vericel Corporation (NASDAQ: VCEL) has announced that the U.S. Food and Drug Administration (FDA) has granted approval for the use of NexoBrid in treating pediatric patients with severe thermal burns. This...
|
| Vericel Corporation
Vericel Corporation (VCEL) has reported a significant surge in revenue in the fiscal first quarter of 2024, with a 25.024% increase to $51.28 million compared to the same period the previous year. This positive news comes at a time when many companies in the Biotechnology & Pharmaceuticals sectors are struggling with declining orders and revenue.
Despite the increase in revenue, Vericel Corporation has reported a loss of $-0.08 per share in the first quarter of 2024. This is a decrease from the earnings per share of $0.27 in the preceding reporting period. The company has also seen a decline in revenue by -21.101% from $65.00 million.
|
| Vericel Corporation
In the ever-evolving world of the stock market, there are always companies that stand out with their exceptional performance and potential for growth. Vericel Corporation (NASDAQ:VCEL) is one such company that has captured the attention and admiration of investors.
Vericel Corporation, renowned for its advanced therapies in the sports medicine and severe burn care markets, has recently reported some impressive financial results for the July to September 2023 period. The company's loss per share decreased from $-0.14 to $-0.08 compared to the same period a year ago, showcasing a significant improvement. Furthermore, earnings per share also experienced a notable increase from $-0.11 in the previous financial reporting period.
|
| Vericel Corporation
Vericel Corporation, a leading Biotechnology & Pharmaceuticals company, has recently released its financial results for the fiscal interval closing June 30, 2023. The report shows positive progress in terms of earnings per share, revenue, and net shortfall.
Firstly, Vericel Corporation has shown a significant improvement in its loss per share, decreasing it to $-0.11 per share compared to $-0.19 in the previous year. This indicates better financial performance and highlights the company's ability to manage its expenses effectively.
|
| Vericel Corporation
Vericel Corporation, a renowned biotechnology and pharmaceutical company, has reported a significant increase in revenue for the financial time-frame ending March 31, 2023. According to the company's financial statements, the revenue increased by 13.702% from the same quarter a year prior to $41.02 million. However, the company recorded a shortfall per share at $-0.16 shortfall per share, which is a cause of concern for the investors.
Interestingly, Vericel Corporation's customers continue to flock to the company, attributing its agile campaign tactics, which focus on attracting clients seeking certainty and value. The company's financial statements show that revenue in the previous quarter fell by -22.16% from $52.69 million. Additionally, the earnings per share (EPS) slid from $0.12 per share, indicating a drop in the company's profits.
|
| Per Share |
Current |
| Earnings (TTM) |
0.01 $ |
| Revenues (TTM) |
4.41 $
|
| Cash Flow (TTM) |
0.1 $ |
| Cash |
2.11 $
|
| Book Value |
4.99 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.01 $
|
| Revenues (TTM) |
4.41 $ |
| Cash Flow (TTM) |
0.1 $ |
| Cash |
2.11 $
|
| Book Value |
4.99 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Change in estimates related to prior periods |
|
 1.03 % |
of total Revenue |
| M A C I Implants and kits |
|
83.81 % |
of total Revenue |
| Through Intermediary MACI implants and kits Contract rate |
|
58.3 % |
of total Revenue |
| Through Intermediary MACI implants and kits Time-and-materials contract |
|
6.33 % |
of total Revenue |
| Time-and-materials contract MACI implants and kits Time-and-materials contract |
|
1.83 % |
of total Revenue |
| Provider or Facility MACI implants and kits Contract rate |
|
15.38 % |
of total Revenue |
| Provider or Facility NexoBrid |
|
1.46 % |
of total Revenue |
| Directly to consumer Biopsy kits |
|
0.93 % |
of total Revenue |
| Directly to consumer Epicel |
|
14.73 % |
of total Revenue |
| |
On May 8 2024 the Vericel provided following guidance
Vericel Corporation, a leading regenerative medicine company, recently announced its financial results for the first quarter of 2024. The company reported a significant increase in total revenue, which rose by 25% to $51.3 million compared to the same period last year.
This strong performance is attributed to the continued growth of Vericel's product portfolio and the successful execution of its business strategy. The company's flagship products have continued to gain traction in the market, driving sales and revenue growth.
In light of this robust financial performance, Vericel has raised its full-year 2024 financial guidance. The company now expects to surpass its previous revenue projections...
|
|
|
